Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed a share repurchase on 18 June 2026, acquiring 160,000 H shares on the Hong Kong Stock Exchange.
The shares were repurchased at prices ranging from HK$3.16 to HK$3.20 apiece, resulting in an average consideration of HK$3.18 per share and an aggregate outlay of HK$0.51 million.
Capital structure impacts: • Issued shares (excluding treasury shares) decreased by 160,000, or 0.0036%, to 4.46306 billion. • Treasury shares increased to 59.27 million. • Total issued shares remained unchanged at 4.52233 billion, as the repurchased shares were retained as treasury stock.
Mandate utilisation: • The buy-back falls under the repurchase mandate approved on 29 May 2026, which authorises Weigao Group to repurchase up to 446.46 million shares. • Cumulative purchases under this mandate now stand at 1.95 million shares, representing 0.44% of the company’s issued share capital on the mandate date.
Pursuant to Hong Kong listing rules, Weigao Group is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 18 July 2026.
Comments